Fig. 3From: Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) Biomarker enrichment and biomarker-driven escalation. a Biomarker enrichment (current strategy—PD-L1 in NSCLC). b Biomarker-directed escalationBack to article page